Please login to the form below
Zontivity
This page shows the latest Zontivity news and features for those working in and with pharma, biotech and healthcare.
FDA reviewer backs approval of TMC's cangrelor
Additional competition in the category will also come from Merck &Co's first-in-class protease-activated receptor-1 (PAR-1) antagonist Zontivity (vorapaxar) - which was cleared for marketing in the
Latest news
-
R&D productivity takes off
Other first-in-class agents include: Merck &Co's PAR-1 antagonist Zontivity (vorapaxar), a novel antiplatelet agent; AstraZeneca's PARP inhibitor Lynparza (olaparib) for cancer; Otsuka's Deltyba (delamanid), a
-
Orphan drugs in latest CHMP recommendations
s Zontivity (vorapaxar), which was recommended for the reduction of atherothrombotic events.
-
Merck's first-in-class Zontivity cleared in US
After a long haul, Merck &Co's Zontivity has become the first drug in the new protease-activated receptor-1 (PAR-1) antagonist class to be approved for marketing in the ... Merck plans to launch Zontivity in the US in the coming weeks, while the PAR-1
-
FDA panel backs Merck's vorapaxar
Vorapaxar - which Merck plans to sell under the brand name Zontivity - is an orally-active protease-activated receptor 1 (PAR-1) inhibitor that targets thrombin-induced platelet activation. ... If the FDA follows the panel's advice - which it generally
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
Deal Watch September 2016
Merck &Co has sold the US and Canadian rights for its Zontivity, or vorapaxar, to Aralez Pharmaceuticals in an asset purchase agreement worth $25m. ... Zontivity is a protease-activated receptor-1 antagonist indicated for use in combination with daily
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Senior Medical Writer
-
Salary TBC
-
Business Director
-
Competitive Salary Offered
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Senior Account Manager
-
Competitive Salary Offered
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Account Director, Medical Education
-
Salary TBC
-
Account Director
-
Competitive Salary Offered
-
Medical Writer
-
Salary TBC
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Global Business Development Director – Health Education
-
excellent commission
-
Associate Director
-
£75, 000-90, 000
-
Account Manager / Account Director
-
Competative
Subscribe to our email news alerts
- China’s clinical trial shake-up
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- Novartis forges AI alliance with Oxford University
- FDA adcomm split on Sanofi’s type 1 diabetes drug
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Essential collaboration skills training for pharma and healthcare teams launched by Dovetail.
PMHub
Accession
Accession was a born from a passion and a vision. A passion to harness the power of market access to...
Latest intelligence
- China’s clinical trial shake-up
- As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Healthcare leaders in the European Union should begin preparing for a breakthrough now...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
Quick links
Infographics
